Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00228384 · ClinicalTrials.gov registry record · Phase 4
GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study
A Phase 4 study, sponsored by W.L.Gore & Associates.
- Completed
- Registry status
- Phase 4
- Development phase
- 148
- Enrollment target
NCT00228384 is a Phase 4 study that has completed, run by W.L.Gore & Associates. The registered enrollment target is 148 participants.
The verdict
NCT00228384, a Phase 4 study, has completed, sponsored by W.L.Gore & Associates.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 148 participants
- Enrollment target
Study Summary
To evaluate the performance of the GORE VIABAHN® Endoprosthesis compared to a bare nitinol stent for the treatment of superficial femoral artery (SFA) occlusive disease in long lesions.
Interventions
- DEVICE GORE VIABAHN Endoprosthesis
- DEVICE Bare Nitinol Stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2005-09 |
| Est. Completion | 2011-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00228384
The ClinicalTrials.gov registry entry for NCT00228384 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GORE VIABAHN Endoprosthesis is the first listed.
NCT00228384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00228384 about?
NCT00228384 is a clinical study titled "GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study". To evaluate the performance of the GORE VIABAHN® Endoprosthesis compared to a bare nitinol stent for the treatment of superficial femoral artery (SFA) occlusive disease in long lesions.
What is the current status of trial NCT00228384?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 148 participants. The study started on 2005-09. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00228384?
The interventions under investigation include: GORE VIABAHN Endoprosthesis (DEVICE), Bare Nitinol Stent (DEVICE).
Who is sponsoring clinical trial NCT00228384?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.